TheranosticTrials.org

Clinical Trial · NCT07660939

GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders

Overview

This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma. Participants will undergo GPRC5D-targeted PET/CT, 18F-FDG PET/CT, and 68Ga-BCMA PET/CT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment. The study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET/CT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.

Sponsor

Peking University First Hospital

Phase

Phase 1

Contacts

Zhao Chen, M.D (CONTACT)

chenzhao0403@163.com

010-83572913

Tingfei Dr. Gu, M.D (CONTACT)

tingfei.gu@stx.ox.ac.uk

010-83572913

Lei Kang, M.D, Ph.D (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07660939

Drug / Compound

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

BCMA

Isotope(s):
Target(s):
  • B-Cell Maturation Antigen (BCMA)

Eligibility

Inclusion

  • Adults with confirmed or suspected plasma cell disorders, including multiple myeloma.
  • Healthy volunteers eligible for PET/CT imaging may also be enrolled.

Exclusion

  • History of other active malignant tumors, unless considered clinically insignificant by the investigator.